Celcuity, Inc. is a pharmaceutical company based in the United States. With an ESG score of 27.9, the company is rated as having medium risk. Specializing in oncology, Celcuity is focused on developing innovative therapies. Their lead candidate, gedatolisib, is a powerful pan-PI3K and mTOR inhibitor with unique properties compared to other therapies on the market. Currently, Celcuity is enrolling patients in a Phase 3 clinical trial, VIKTORIA-1, to evaluate gedatolisib in combination with fulvestrant for patients with advanced breast cancer.